The Distribution of BSH in Patients with Malignant Glioma

One of the goals of the European Collaboration on Boron Neutron Capture Therapy is to treat gliomas, using Na2B12H11SH (BSH) as boron carrier. In order to treat these tumors with boron neutron capture therapy, it is necessary to accumulate sufficient amounts of boron in the tumor prior to irradiation, and at the same time ensure that healthy tissue unavoidably present in the neutron beam contains a minimal amount of boron. The concentration of boronated compounds in the tissues eventually exposed to the neutron beam is of utmost importance for the prediction of healthy tissue damage and tumor control. Within the European Collaboration, a study of the distribution of BSH has therefore been started.